Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.
Location: United States, New York
Employees: 51-200
Total raised: $61M
Founded date: 2015
Investors 3
| Date | Name | Website |
| - | dRx Capita... | drxcapital... |
| 28.09.2020 | McKesson V... | ventures.m... |
| 09.06.2024 | dRx Capita... | live-drxca... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.02.2022 | Series C | $45M | - |
| 29.09.2020 | Series B | $16M | - |
Mentions in press and media 18
| Date | Title | Description |
| 28.06.2023 | Koneksa Appoints Dave Hurry as Chief Data Officer and Dr. Larsson Omberg as EVP of Data Science | Koneksa, the evidence-based digital biomarkers company, announced the appointment of Dave Hurry as Chief Data Officer and Larsson Omberg, Ph.D., as Executive Vice President of Data Science. Both executives will be joining the company’s lead... |
| 10.03.2023 | Chris Benko, co-founder and CEO of Koneksa Health, on VatorNews podcast | Koneksa Health is a company that is developing, testing, and validating digital biomarkers Vator · Interview with Chris Benko, CEO at Koneksa Health Steven Loeb speaks with Chris Benko, co-founder and CEO of Koneksa Health, a company that i... |
| 14.02.2022 | Digital health news, funding roundup in the prior week; February 14, 2022 | Amazon expanded its on-demand health solution; Medable partnered with CVS; COVID deaths passed 900k Top Health News Amazon Care, the company's on-demand healthcare solution, expanded to employees in all 50 states Digital clinical trials com... |
| 08.02.2022 | Koneksa secures $45M for digital biomarker platform | Koneksa has raised a $45 million Series C led by AyurMaya, an affiliate of Matrix Capital Management, with participation from Takeda Ventures and Velosity Capital. Koneksa's healthcare platform is designed to remotely collect and analyze pa... |
| 08.02.2022 | Koneksa Raises $45M in Series C Funding | Koneksa, a New York-based company focused on designing and validating digital biomarkers, raised $45M in Series C funding. The round was led by AyurMaya with participation from Takeda Ventures and Velosity Capital, as well as existing inves... |
| 07.02.2022 | Koneksa Raises $45M Series C | NEW YORK, NY, Koneksa, a leader in designing and validating digital biomarkers, announced the completion of a $45M Series C, led by AyurMaya. >> Click here for more funding data on Koneksa >> To export Koneksa funding data t... |
| 07.02.2022 | Koneksa Raises $45M Series C Financing to Accelerate Expansion of Digital Biomarker Platform | Koneksa, the leader in designing and validating digital biomarkers to accelerate drug development, announced today the completion of a $45M Series C financing round, led by AyurMaya, an affiliated fund of Matrix Capital Management, with par... |
| 07.02.2022 | Digital biomarker startup Koneksa scores $45M in Series C funding | Photo: Kwanchai Lerttanapunyaporn/Getty Images |
| 07.02.2022 | Frontier and Spirit Airlines to take on the pandemic-induced travel hiatus with $6.6B deal | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Frontier Airlines announced it had agreed to purchase its low-cost rival Spirit Airlines this mor... |
| 07.02.2022 | Takeda joins Novartis and Merck in $45M funding for Koneksa Health | Takeda Ventures has joined Novartis and Merck in backing Koneksa Health, which bills itself as a digital biomarker company. Koneksa's platform stands to benefit from the renewed interest the COVID-19 pandemic brought to remote monitoring of... |
Show more